Breaking News

Frontage Labs Names COO

By Gil Roth | February 18, 2014

Orantes to lead U.S. operations

Carlos Orantes has been appointed chief operating officer of Frontage Laboratories. A 20-year veteran of contract research and life science industries, he will lead Frontage’s U.S. operations, which comprise a 60,000-sq.-ft. laboratory for bioanalysis and DMPK functions, an 88-bed clinical research unit and a portfolio of CMC services, including product development, analytical testing and CTM manufacturing.

Mr. Orantes previously served as president and chief executive officer of AVANZA Laboratories. There, he developed the company’s business strategy, and led activities related to the company’s asset purchase in 2012 by the Smithers Group. Prior to AVANZA, Mr. Orantes was general manager and vice president for Bridge Laboratories, a toxicology and immunology testing laboratory where he held management responsibility for US operations.

“Mr. Orantes brings an impressive record of designing and leading successful growth strategies for companies that are large and small, both private and publicly-held entities,” said Dr. Song Li, Frontage's chairman and chief executive officer. “Our goal is to expand our service offerings to meet shifting industry needs, and make it easier for customers to do business with us by bringing technical guidance, excellent customer service along with new services to solve the needs of our customers. I’m confident that Frontage and our customers will significantly benefit from his business experience driving strategic initiatives as the company enters its next phase of growth.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important